ClinicalTrials.gov
public full text
Public Domain
A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients
* To investigate the safety of once-daily repeated transdermal administration of SPM 962 within a dose range of 4.5 to 36.0 mg/day (54-week treatment period) in Parkinson's disease (PD) patients treated concomitantly with L-dopa in a multi-center, open-label uncontrolled study. * To investigate efficacy of SPM 962 in an exploratory manner.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients#855651
- Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)#1057994
- Pharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor Fluctuations#828036
- The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa#862982
- Clinical Trial on the Effectiveness of Herbal Medicinal Mixture in Parkinson Disease#898359
Record · ID 833795
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive